---
layout: default
title: Tyrosine
description: "Tyrosine 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 187
evidence_level: L3
indication_count: 10
---

# Tyrosine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tyrosine 藥師評估報告

## 一句話總結

<p class="key-answer" data-question="Tyrosine 可以用於治療什麼新適應症？">
Tyrosine (酪氨酸) 是一種非必需胺基酸，TxGNN 預測其可能對多種甲狀腺疾病及神經系統疾病具有潛在療效，其中甲狀腺相關預測具有較強的生化機制支持。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥物名稱 | Tyrosine (酪氨酸 / L-Tyrosine) |
| DrugBank ID | DB00135 |
| 原核准適應症 | 胺基酸營養補給劑 |
| 預測新適應症數量 | 10 項 |
| 最高預測分數適應症 | 馬尾症候群，分數 0.998 |
| 臨床試驗支持 | 有限，主要為間接相關 |
| 文獻證據 | 甲狀腺相關文獻較豐富 |
| 台灣上市狀態 | 多為已註銷之原料藥 |

---



## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. cauda equina syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.77%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 預測機制分析</p>

<ol>
<li><strong>甲狀腺功能亢進 (Hyperthyroidism)</strong> - TxGNN 分數: 0.995</li>
</ol>
<ul>
<li><strong>機制明確</strong>：Tyrosine 是甲狀腺素 (T3/T4) 合成的必需前驅物</li>
<li>有 4 項臨床試驗及 20+ 篇 PubMed 文獻支持</li>
<li>文獻 PMID: 36848916 詳細描述甲狀腺功能亢進的病因學，提及 tyrosine kinase 抑制劑可誘發甲狀腺功能異常</li>

</ul>
<ol>
<li><strong>甲狀腺素過多血症 (Hyperthyroxinemia)</strong> - TxGNN 分數: 0.995</li>
</ol>
<ul>
<li>與甲狀腺素代謝直接相關</li>
<li>文獻 PMID: 40171189 報導 Levodopa 誘導甲狀腺功能調節的案例，涉及多巴胺-甲狀腺軸</li>

</ul>
<ol>
<li><strong>姿位性心搏過速症候群 (POTS)</strong> - TxGNN 分數: 0.995</li>
</ol>
<ul>
<li>有 1 項臨床試驗 (NCT00580619) 涉及自主神經系統與慢性疲勞</li>
<li>文獻 PMID: 39063020 報導使用 alpha-methyl-p-tyrosine (AMPT) 治療慢性疲勞合併 POTS 的案例</li>

</ul>
<ol>
<li><strong>隅角閉鎖型青光眼</strong> - TxGNN 分數: 0.995</li>
</ol>
<ul>
<li>有 6 篇相關文獻，涉及 tyrosine kinase 在眼壓調控中的角色</li>
<li>文獻 PMID: 22568104 討論 SRC tyrosine kinase 在青光眼護理中的意義</li>

</ul>
<ol>
<li><strong>新生血管性青光眼 (Neovascular Glaucoma)</strong> - TxGNN 分數: 0.993</li>
</ol>
<ul>
<li>有 2 項臨床試驗 (NCT05131646, NCT04626128) 評估 tyrosine kinase 抑制劑</li>
<li>文獻 PMID: 22898649 討論 anti-VEGF 療法與 tyrosine kinase 抑制劑在眼部新生血管的角色</li>
</ul>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

<h3>相關文獻</h3>

<p>### 相關 PubMed 文獻</p>

<table>
<thead>
<tr>
<th>適應症</th>
<th>文獻數量</th>
<th>代表性文獻</th>
</tr>
</thead>
<tbody>
<tr>
<td>甲狀腺功能亢進</td>
<td>20+</td>
<td>PMID: 36848916 - 甲狀腺功能亢進完整回顧</td>
</tr>
<tr>
<td>POTS</td>
<td>4</td>
<td>PMID: 31412221 - POTS 機制與新療法</td>
</tr>
<tr>
<td>青光眼</td>
<td>6</td>
<td>PMID: 32222418 - 過氧亞硝酸與青光眼</td>
</tr>
<tr>
<td>甲狀腺激素阻抗</td>
<td>8</td>
<td>PMID: 10579356 - THR beta 受體突變</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. obsolete neurogenic bladder (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. angle-closure glaucoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.54%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（6 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27758063/" target="_blank">27758063</a></td><td>2017</td><td>Article</td><td>Clinical &amp; experimen</td><td>Course of serum autoantibodies in patients after acute angle...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34558166/" target="_blank">34558166</a></td><td>2021</td><td>Article</td><td>Veterinary ophthalmo</td><td>Proteomic analysis of aqueous humor in canine primary angle-...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15534476/" target="_blank">15534476</a></td><td>2004</td><td>Article</td><td>Journal of glaucoma</td><td>Neuronal nitric oxide synthase (nNOS) positive retinal amacr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32222418/" target="_blank">32222418</a></td><td>2020</td><td>Article</td><td>Nitric oxide : biolo</td><td>Peroxynitrite is a novel risk factor and treatment target of...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22568104/" target="_blank">22568104</a></td><td>2012</td><td>Article</td><td>Nippon Ganka Gakkai </td><td>[Toward a high quality glaucoma care].</td></tr>
</tbody>
</table>
<p><em>...及其他 1 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hyperthyroidism</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.51%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（4 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07200882" target="_blank">NCT07200882</a></td><td>N/A</td><td>NOT_YET_RECRUITING</td><td>76</td><td>Assessment of Tyrosine Kinase Inhibitors on Thyroid Functions in Patients With C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04809454" target="_blank">NCT04809454</a></td><td>N/A</td><td>UNKNOWN</td><td>100</td><td>Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06264544" target="_blank">NCT06264544</a></td><td>NA</td><td>NOT_YET_RECRUITING</td><td>150</td><td>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Ef...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04740307" target="_blank">NCT04740307</a></td><td>PHASE2</td><td>COMPLETED</td><td>116</td><td>A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36848916/" target="_blank">36848916</a></td><td>2023</td><td>Article</td><td>The lancet. Diabetes</td><td>Hyperthyroidism: aetiology, pathogenesis, diagnosis, managem...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34913664/" target="_blank">34913664</a></td><td>2021</td><td>Article</td><td>American family phys</td><td>Thyroiditis: Evaluation and Treatment.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38044176/" target="_blank">38044176</a></td><td>2024</td><td>Article</td><td>Seminars in nuclear </td><td>Autoimmune Thyroid Diseases.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38108994/" target="_blank">38108994</a></td><td>2024</td><td>Article</td><td>Reviews in endocrine</td><td>The genetics of Graves&#x27; disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4414985/" target="_blank">4414985</a></td><td>1974</td><td>Article</td><td>European neurology</td><td>Parkinsonism and hyperthyroidism.</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. postural orthostatic tachycardia syndrome</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.46%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00580619" target="_blank">NCT00580619</a></td><td>PHASE1</td><td>COMPLETED</td><td>170</td><td>Autonomic Nervous System and Chronic Fatigue Syndrome</td></tr>
</tbody>
</table>

<h3>相關文獻（4 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31412221/" target="_blank">31412221</a></td><td>2020</td><td>Article</td><td>Annual review of med</td><td>Postural Orthostatic Tachycardia Syndrome: Mechanisms and Ne...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15710782/" target="_blank">15710782</a></td><td>2005</td><td>Article</td><td>Hypertension (Dallas</td><td>Hyperadrenergic postural tachycardia syndrome in mast cell a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39063020/" target="_blank">39063020</a></td><td>2024</td><td>Article</td><td>International journa</td><td>Stress-Related Chronic Fatigue Syndrome: A Case Report with ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12403667/" target="_blank">12403667</a></td><td>2002</td><td>Article</td><td>Circulation</td><td>Cardiac sympathetic dysautonomia in chronic orthostatic into...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hyperthyroxinemia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.46%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（5 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40171189/" target="_blank">40171189</a></td><td>2025</td><td>Article</td><td>Frontiers in endocri</td><td>Levodopa induces thyroid function regulation in a patient wi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12677005/" target="_blank">12677005</a></td><td>2003</td><td>Article</td><td>Molecular endocrinol</td><td>A thyrotoxic skeletal phenotype of advanced bone formation i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/176774/" target="_blank">176774</a></td><td>1976</td><td>Article</td><td>Virchows Archiv. B, </td><td>Pigmentation and dysfunction of Gunn rat thyroid: correlatio...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10579356/" target="_blank">10579356</a></td><td>1999</td><td>Article</td><td>Endocrinology</td><td>Three novel mutations at serine 314 in the thyroid hormone b...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19169471/" target="_blank">19169471</a></td><td>2008</td><td>Article</td><td>Arquivos brasileiros</td><td>E449X mutation in the thyroid hormone receptor beta associat...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（8 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18683837/" target="_blank">18683837</a></td><td>2008</td><td>Article</td><td>Angewandte Chemie (I</td><td>Selective chemical rescue of a thyroid-hormone-receptor muta...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15135777/" target="_blank">15135777</a></td><td>2004</td><td>Article</td><td>Growth hormone &amp; IGF</td><td>Molecular mechanisms of end-organ resistance.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12677005/" target="_blank">12677005</a></td><td>2003</td><td>Article</td><td>Molecular endocrinol</td><td>A thyrotoxic skeletal phenotype of advanced bone formation i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2153155/" target="_blank">2153155</a></td><td>1990</td><td>Article</td><td>The Journal of clini</td><td>A base mutation of the C-erbA beta thyroid hormone receptor ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10579356/" target="_blank">10579356</a></td><td>1999</td><td>Article</td><td>Endocrinology</td><td>Three novel mutations at serine 314 in the thyroid hormone b...</td></tr>
</tbody>
</table>
<p><em>...及其他 3 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. aqueous misdirection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.35%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. traumatic glaucoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.35%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22644448/" target="_blank">22644448</a></td><td>2012</td><td>Article</td><td>Japanese journal of </td><td>Retinal remodeling.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. neovascular glaucoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.32%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05131646" target="_blank">NCT05131646</a></td><td>N/A</td><td>COMPLETED</td><td>15</td><td>Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04626128" target="_blank">NCT04626128</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>27</td><td>OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerabil...</td></tr>
</tbody>
</table>

<h3>相關文獻（4 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35087972/" target="_blank">35087972</a></td><td>2021</td><td>Article</td><td>Romanian journal of </td><td>A review of neovascular glaucoma. Etiopathogenesis and treat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35060431/" target="_blank">35060431</a></td><td>2022</td><td>Article</td><td>Expert opinion on th</td><td>Disease progression pathways of wet AMD: opportunities for n...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22898649/" target="_blank">22898649</a></td><td>2012</td><td>Article</td><td>Survey of ophthalmol</td><td>Corneal neovascularization: an anti-VEGF therapy review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29856367/" target="_blank">29856367</a></td><td>2018</td><td>Article</td><td>The Journal of clini</td><td>Gene therapy and genome surgery in the retina.</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

### 許可證狀態

| 許可證字號 | 中文品名 | 劑型 | 許可證持有者 | 狀態 |
|------------|----------|------|--------------|------|
| 衛署藥輸字第004172號 | 協和 L-酪氨酸 | 原料藥 | 裕元興業 | 已註銷 |
| 衛署藥輸字第006340號 | 味之素 乾酪氨酸 | 原料藥 | 東信化學 | 已註銷 |
| 衛署藥輸字第007503號 | 左酪氨酸 | 原料藥 | 興源藥品 | 已註銷 |
| 衛署藥輸字第021614號 | 乾酪氨酸 | 原料藥 | 臺田藥品 | 已註銷 |

**備註**：純 L-Tyrosine 原料藥許可證均已註銷，但含有 tyrosine kinase 抑制劑的藥品 (如英可欣、杰百康) 仍有有效許可證。

---

## 安全性資訊

### 藥物交互作用 (DDI)

**根據 DDinter 資料庫：無已知重大藥物交互作用**

Tyrosine 作為天然胺基酸，整體安全性良好。

### 使用注意事項

1. **甲狀腺疾病患者**：補充 tyrosine 可能影響甲狀腺激素合成
2. **使用 MAO 抑制劑者**：理論上可能增加酪胺反應風險
3. **苯酮尿症 (PKU) 患者**：phenylalanine 代謝異常，tyrosine 補充需謹慎評估
4. **高劑量使用**：可能出現腸胃不適、頭痛、疲勞

### 已知副作用

- 一般耐受性良好
- 偶見：噁心、頭痛、疲勞、心悸
- 高劑量可能影響血壓

---

## 結論

### 整體評估

Tyrosine 作為甲狀腺激素和兒茶酚胺的生物合成前驅物，其在甲狀腺相關疾病的預測具有明確的生化基礎。對於 POTS 和青光眼的預測則需要更多直接證據。

### 建議

1. **甲狀腺功能異常相關研究** - 值得進一步探索，但需注意可能加重甲亢症狀
2. **POTS 相關應用** - 可考慮小規模探索性研究，已有 AMPT 相關研究基礎
3. **營養補充層面** - 對於 tyrosine 缺乏或需求增加的情況，可作為輔助治療考量

### 證據等級

| 類別 | 評級 |
|------|------|
| 預測可信度 | 中至高 (甲狀腺相關)；中等 (其他) |
| 臨床證據 | 中等 (有間接試驗) |
| 安全性顧慮 | 低 (天然胺基酸) |
| 老藥新用潛力 | 中等 |

---

*報告產生日期：2026-02-11*
*資料來源：TxGNN 知識圖譜、PubMed、ClinicalTrials.gov、台灣 FDA*


---

## 相關藥物報告

- [Nebivolol]({{ "/drugs/nebivolol/" | relative_url }}) - 證據等級 L5
- [Fenoterol]({{ "/drugs/fenoterol/" | relative_url }}) - 證據等級 L5
- [Diosmin]({{ "/drugs/diosmin/" | relative_url }}) - 證據等級 L5
- [Tazarotene]({{ "/drugs/tazarotene/" | relative_url }}) - 證據等級 L5
- [Bempedoic Acid]({{ "/drugs/bempedoic_acid/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Tyrosine老藥新用驗證報告. https://twtxgnn.yao.care/drugs/tyrosine/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_tyrosine,
  title = {Tyrosine老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tyrosine/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
